



OptiCor
PERSONALISED CV CARE

Digital Personalized Cardiovascular Care

Optimize CV treatment and outcomes with OptiCor™



Individual risk prediction



Personalized, guideline-based recommendations for treatments and interventions



Fits within current clinical practice workflow



EHR integration and compatibility

INTEGRATION
POWERED BY REDOX™

Your risk profile for: 5/17/2022

CHA2DS2-VASc: 4

Individual risk profile

1-year risk in %

Mortality risk

Reduction in risk: -50% ↓

Current 9.5
Adjusted 4.7

Stroke risk

Reduction in risk: -51% ↓

Current 2.0
Adjusted 1.0

Bleeding risk

Reduction in risk: -31% ↓

Current 1.8
Adjusted 1.3

Recommendations

Uncheck boxes below to view effect on adjusted risk

Anticoagulation

Oral anticoagulation is recommended. Consider switching from VKA to a non-vitamin K antagonist (NOAC), if no contraindications. Renal and hepatic function should be evaluated before initiation of a NOAC and should be reevaluated at least annually

Catheter Ablation

Your patient meets the eligibility criteria for a primary catheter ablation or antiarrhythmic therapy. Consider referral to electrophysiologist.

Diabetes medication

Because of your patient's diabetes and high cardiovascular risk, consider starting an SGLT2-inhibitor or GLP-1RA with proven cardiovascular benefit depending on patient-specific factors and co-morbidities

Smoking cessation

Smoking cessation counseling is recommended for your patient

tenac.io 52,000 patient study published in European Heart Journal Digital Health

[Read here!](#)



tenac.io

tenac.io, Inc.
447 Broadway, 2/F
New York, NY 10013, USA

tenac.io GmbH
Oberwallstrasse 6,
10117 Berlin, Germany